Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.383
+0.002 (0.45%)
At close: Apr 28, 2026, 4:00 PM EDT
0.399
+0.016 (4.20%)
Pre-market: Apr 29, 2026, 8:39 AM EDT
Scienture Holdings Revenue
In the year 2025, Scienture Holdings had annual revenue of $431.61K with 215.87% growth. Scienture Holdings had revenue of $-168.70K in the quarter ending December 31, 2025, a decrease of -417.80%.
Revenue (ttm)
$431.61K
Revenue Growth
+215.87%
P/S Ratio
36.05
Revenue / Employee
$47,957
Employees
9
Market Cap
15.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 431.61K | 294.97K | 215.87% |
| Dec 31, 2024 | 136.64K | -1.23M | -89.98% |
| Dec 31, 2023 | 1.36M | 1.06M | 354.61% |
| Dec 31, 2022 | 300.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSCNX News
- 4 weeks ago - SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions - GlobeNewsWire
- 3 months ago - SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 3 months ago - SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment - GlobeNewsWire
- 4 months ago - SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA - GlobeNewsWire
- 5 months ago - SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium - GlobeNewsWire
- 5 months ago - SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025 - GlobeNewsWire
- 5 months ago - SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update - GlobeNewsWire